ABL Bio Inc (298380) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.179x

Based on the latest financial reports, ABL Bio Inc (298380) has a cash flow conversion efficiency ratio of 0.179x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩32.84 Billion ≈ $22.26 Million USD) by net assets (₩183.34 Billion ≈ $124.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 298380 net asset quality score to measure how much of total assets are equity-financed.

ABL Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how ABL Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABL Bio Inc (298380) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

ABL Bio Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ABL Bio Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shenzhen Intellifusion Technologies Co. Ltd. A SHG:688343	N/A
Xenon Pharmaceuticals Inc NASDAQ:XENE	-0.140x
SSAB AB (publ) ST:SSAB-A	0.005x
Tegna Inc NYSE:TGNA	0.034x
JUMBO SA UNSP.ADR/1 O.N. F:5JB1	N/A
MeiHua Holdings Group Co Ltd SHG:600873	0.150x
Nuvama Wealth NSE:NUVAMA	N/A
Liberty Oilfield Services Inc NYSE:LBRT	0.094x

Annual Cash Flow Conversion Efficiency for ABL Bio Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of ABL Bio Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 298380 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩156.70 Billion ≈ $106.19 Million	₩-41.25 Billion ≈ $-27.96 Million	-0.263x	+36.55%
2024-12-31	₩167.28 Billion ≈ $113.36 Million	₩-69.40 Billion ≈ $-47.03 Million	-0.415x	-8.37%
2023-12-31	₩74.08 Billion ≈ $50.20 Million	₩-28.36 Billion ≈ $-19.22 Million	-0.383x	-136.90%
2022-12-31	₩69.51 Billion ≈ $47.11 Million	₩72.13 Billion ≈ $48.88 Million	1.038x	+242.99%
2021-12-31	₩55.95 Billion ≈ $37.92 Million	₩-40.61 Billion ≈ $-27.52 Million	-0.726x	-39.12%
2020-12-31	₩90.66 Billion ≈ $61.44 Million	₩-47.29 Billion ≈ $-32.05 Million	-0.522x	-188.67%
2019-12-31	₩132.01 Billion ≈ $89.46 Million	₩-23.86 Billion ≈ $-16.17 Million	-0.181x	-123.90%
2018-12-31	₩156.96 Billion ≈ $106.37 Million	₩-12.67 Billion ≈ $-8.59 Million	-0.081x	-197.13%
2017-12-31	₩-85.96 Billion ≈ $-58.25 Million	₩-7.14 Billion ≈ $-4.84 Million	0.083x	-67.72%
2016-12-31	₩-12.10 Billion ≈ $-8.20 Million	₩-3.12 Billion ≈ $-2.11 Million	0.257x	--

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$3.24 Billion

₩4.77 Trillion KRW

Market Cap Rank

#4696 Global

#107 in Korea

Share Price

₩86600.00

Change (1 day)

+3.96%

52-Week Range

₩60800.00 - ₩245500.00

All Time High

₩245500.00